212 related articles for article (PubMed ID: 23676603)
1. Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
Kurasawa T; Nagasawa H; Nishi E; Takei H; Okuyama A; Kondo T; Nishimura K; Sakai R; Shibata A; Chino K; Ogawa H; Ito T; Amano K; Kato H
Intern Med; 2013; 52(10):1125-30. PubMed ID: 23676603
[TBL] [Abstract][Full Text] [Related]
2. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.
Fujinaga S; Kaneko K; Ohtomo Y; Murakami H; Takada M; Akashi S; Hira M; Yamashiro Y
Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476
[TBL] [Abstract][Full Text] [Related]
3. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.
Nomura A; Shimizu H; Kishimoto M; Suyama Y; Rokutanda R; Ohara Y; Yamaguchi K; Okada M
Lupus; 2012 Nov; 21(13):1444-9. PubMed ID: 22917589
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
7. Intravenous cyclophosphamide pulse therapy in Japanese children with systemic lupus erythematosus.
Igarashi T; Igarashi T; Shimizu A; Itoh Y
J Nippon Med Sch; 2013; 80(5):396-400. PubMed ID: 24189359
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis.
Tanaka H; Aizawa T; Watanabe S; Oki E; Tsuruga K; Imaizumi T
Lupus; 2014 Jul; 23(8):813-8. PubMed ID: 24651669
[TBL] [Abstract][Full Text] [Related]
10. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis.
Kagawa H; Hiromasa T; Hara T; Takaki A; Yamanaka R; Sada KE; Makino H
Clin Exp Nephrol; 2012 Oct; 16(5):760-6. PubMed ID: 22492013
[TBL] [Abstract][Full Text] [Related]
11. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis.
El-Sehemy MS; Al-Saaran AM; Baddour NM; Adam AG; Moez PE
Egypt J Immunol; 2006; 13(1):39-52. PubMed ID: 17974149
[TBL] [Abstract][Full Text] [Related]
12. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
13. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
Yap DY; Yu X; Chen XM; Lu F; Chen N; Li XW; Tang CS; Chan TM
Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis.
Kawazoe M; Nanki T
Lupus; 2024 Apr; 33(4):319-327. PubMed ID: 38232223
[TBL] [Abstract][Full Text] [Related]
15. Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.
Zheng Z; Zhang H; Peng X; Zhang C; Xing C; Xu G; Fu P; Ni Z; Chen J; Xu Z; Zhao MH; Li S; Huang X; Miao L; Chen X; Liu B; He Y; Li J; Liu L; Kadeerbai H; Liu Z; Liu Z
JAMA Netw Open; 2022 Mar; 5(3):e224492. PubMed ID: 35353167
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China.
Kim S; Reen Ooi AY; Stephens T; Jiang H
J Comp Eff Res; 2019 Oct; 8(13):1125-1141. PubMed ID: 31580156
[No Abstract] [Full Text] [Related]
17. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
18. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe lupus nephritis: the new horizon.
Chan TM
Nat Rev Nephrol; 2015 Jan; 11(1):46-61. PubMed ID: 25421826
[TBL] [Abstract][Full Text] [Related]
20. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
